222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
October 2021 in “International Journal of Research in Dermatology” People with alopecia areata often have low vitamin D levels, which may worsen their hair loss.
June 2024 in “British Journal of Dermatology” A 15-year-old boy was correctly diagnosed with a rare skin condition after initially being misdiagnosed.
January 2023 in “Przegla̧d dermatologiczny” There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
38 citations,
June 2015 in “PubMed” Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
2 citations,
May 2022 in “JAAD Case Reports” A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
January 2024 in “Skin appendage disorders” Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
2 citations,
March 2022 in “Dermatologic Therapy” Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
47 citations,
June 2017 in “Journal of dermatology” New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
11 citations,
May 2021 in “Journal of The American Academy of Dermatology” COVID-19 doesn't make alopecia areata worse.
1 citations,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
1 citations,
January 2022 in “The Egyptian Journal of Hospital Medicine ” Cryotherapy and steroid injections are similarly effective and safe for treating alopecia areata.
February 2023 in “Global journal of health sciences and research” Zinc levels are not significantly linked to the presence or severity of alopecia areata.
47 citations,
December 2020 in “Journal of the European Academy of Dermatology and Venereology” The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.